DISEASE INDICATIONS: Acute Hepatic Porphyria (AHP)

MANUFACTURER: Alnylam Pharmaceuticals

USAGE: Subcutaneous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Pharmaceuticals and Medical Devices Agency (PMDA)

Givlaari (givosiran) is a synthetic small interfering RNA medication given as a monthly subcutaneous injection to prevent attacks of acute intermittent porphyria by reducing the production of the liver enzyme ALAS1, which leads to toxic heme precursors accumulation.